Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action

Colorectal Cancer Clinical Trial

Official title:

Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02125409
• Other study ID #: D-13-01
• Secondary ID: 2013-004269-15
• Status: Not yet recruiting
• Phase: Phase 3
• First received: April 25, 2014
• Last updated: May 2, 2014
• Start date: May 2014

Study information

• Verified date: May 2014
• Source: Aragon Institute of Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Agencia Española de Medicamentos y Productos Sanitarios
• Study type: Interventional

Clinical Trial Summary

In a preliminary study in healthy subjects, the investigators determined the pharmacokinetic and pharmacodynamic of enteric-coated acetylsalicylic acid (ASA) (Adiro 100 mg, Bayer), and the variability (coefficient of variation), accuracy and precision of a novel biomarker of ASA action, i.e., quantification of the extent of COX-1 acetylation at serine-529, using a stable isotope dilution liquid chromatography multiple reaction monitoring/mass spectrometry (LC-MS) technique.

Now, the investigators will perform a clinical study in individuals undergoing Colorectal cancer (CRC) to validate the hypothesis that that low-dose ASA given once daily is acting primarily by selectively acetylating platelet COX-1 and suppressing its activity throughout the 24-hour dosing interval. In contrast, it is expected that the inhibitory effect on extra-platelet sources of COX-1 will be short-lasting, if any, affecting only partially COX-1, and this effect will be completely reversed at 24 hours after dosing. This is an important point which will strengthen the platelet hypothesis underpinning the apparent adequacy of a 24-hour dosing interval of ASA administration for the anticancer effect detected in cardiovascular trials.

These patients will be stratified into individuals with adenomas/carcinomas (20 to 30%) and patients without clinically detected adenomas/carcinomas (about 70 to 80%).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. primary completion date: May 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 69 Years

Eligibility

Inclusion Criteria:

1. Men and women, aged = 18 and = 69.

2. Patients should have an indication for screening colonoscopy

1. First degree relative of patient with CRC.

2. Personal history of adenomas.

3. People older than 50 and FOBT positive

3. Routine hematological and biochemical parameters within the normal range.

Exclusion Criteria:

1. Allergy to ASA or other NSAIDs.

2. Previous use of ASA, NSAIDS, antiplatelet agents, corticosteroids or misoprostol in the previous 15 days and/or anticipated need for these drugs during the study period.

3. Peptic ulcer history or any other gastrointestinal disease that could be considered a contraindication for ASA use without the concomitant use of a proton-pump inhibitor.

4. Subjects with coagulation disorder or serious comorbid condition.

5. Malignancies, excluding CRC, diagnosed in the previous 5 years

6. Cigarette smoking, history of drug or alcohol abuse

7. Pregnant women or breast feeding

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Drug:
• Acetylsalicylic acid
One tablet of Adiro 100 mg will be administered daily for 7 days.

Procedure:
• Screening colonoscopy

Locations

Country	Name	City	State
Spain	Hospital Clínico Universitario Lozano Blesa	Zaragoza

Sponsors (3)

Lead Sponsor	Collaborator
Aragon Institute of Health Sciences	Catholic University, Italy, G. d'Annunzio University

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of the degree of COX-1 acetylation by ASA administered for 1 week.	It will be performed in platelets versus biopsies of the recto-colonic tissues.	7 hours after the 7th daily dose (group 1) and 24 hours after the 7th daily dose (group 2)	No
Secondary	Changes from baseline in different biomarkers.	It will be used a combining technique of liquid chromatography with mass spectrometry (LC-MS/MS) to quantify the level of acetylation of COX-1 in circulating platelets in subjects treated with ASA.; Parameters of the composite measure: haemochrome, AST, ALT, gamma-GT, alkaline phosphatase (AP), total bilirubin, total protein, glucose, creatinine, N, Na, K, Ca.; urine analysis: pH, protein, albumin, glucose, RBC, bilirubin, nitrites, leucocytes and sediment.	pre-drug on day 0 and after the 7th daily dose (6 hours for Group 1 and 24 hours for Group 2)	Yes
Secondary	Changes from baseline in eicosanoid generation in vivo by measuring urinary metabolites derived from COXs.	It will be performed by ultra-performance liquid chromatography tandem mass spectrometry-mass spectrometry (UPLC/MS/MS).	pre-drug on day 0 and after the 7th daily dose (6 hours for Group 1 and 24 hours for Group 2)	No
Secondary	Changes in baseline platelet COX-1	By using human whole blood assay (serum TXB2) ex vivo	pre-drug on day 0 and after the 7th daily dose (6 hours for Group 1 and 24 hours for Group 2)	No
Secondary	Change from baseline in plasma proteins of markers of angiogenesis.	In blood sample by using an antibody array kit and Sphingosine-1 Phosphate (S1P) by immunoassay.	pre-drug on day 0 and after the 7th daily dose (6 hours for Group 1 and 24 hours for Group 2)	No
Secondary	Assessment of ASA plasma levels.	Will be performed whole blood aggregation test.	pre-drug on day 0 and after the 7th daily dose (6 hours for Group 1 and 24 hours for Group 2)	No
Secondary	Changes from baseline of proteomic profile of selected angiogenesis factors, ie VEGF, FGF2, TGFbeta, EGF, PDGF, MMP, angiogenin, and angiogenesis inhibitors, ie endostatin, PF4, thrombospondin 1, alpha-macroglobulin, PAI 1 and angiostatin.	It will be done in isolated platelets by using an antibody array kit and Sphingosine-1 Phosphate (S1P) by immunoassay.	pre-drug on day 0 and after the 7th daily dose (6 hours for Group 1 and 24 hours for Group 2)	No
Secondary	Change from baseline in eicosanoid biosynthesis and protein expression of markers of growth and progression of colorectal cancer (such as COX-2, NF-Kb and PI3K/Akt/mTOR pathway).	It will be done in normal tissues or pathological recto-colonic tissues.	pre-drug on day 0 and after the 7th daily dose (6 hours for Group 1 and 24 hours for Group 2)	No